The Korean Journal of Medicine

  • 제87권6호
  • /
  • Pages.686-689
  • /
  • 2014
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

당뇨병 환자에서 이상지질혈증의 치료

Dyslipidemia Treatment in Diabetes Mellitus Patients

  • 김성래 (가톨릭대학교 의과대학 내분비대사내과)
  • Kim, Sung Rae (Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea)
  • 발행 : 2014.12.01
⟨ 이전 논문 다음 논문 ⟩

초록

Cardiovascular disease (CVD) is the major cause of mortality and morbidity in patients with type 2 diabetes mellitus. The increased risk of CVD in subjects with type 2 diabetes mellitus involves multiple factors, including hypertension, smoking, albuminuria, and hypercholesterolemia. Of these, hypercholesterolemia is amenable to intervention. A large body of research ranging from molecular to population studies indicates that elevated low-density-lipoprotein cholesterol (LDL-C) is a major predictor of CVD, including in the population with diabetes. Despite available therapies and increased attention to hypercholesterolemia, many patients fail to achieve the LDL-C goals. A patient-tailored approach to dyslipidemia therapy, as determined by baseline LDL-C levels, is an effective strategy for achieving target LDL-C levels.

키워드

참고문헌

  1. Bloomgarden ZT. Diabetes and cardiovascular disease. Diabetes Care 2011;34:e24-30. https://doi.org/10.2337/dc11-0007
  2. Webb DR, Khunti K, Gray LJ, et al. Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected Type 2 diabetes mellitus: a cluster randomized controlled trial. Diabet Med 2012;29:531-540. https://doi.org/10.1111/j.1464-5491.2011.03441.x
  3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497. https://doi.org/10.1001/jama.285.19.2486
  4. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-239. https://doi.org/10.1161/01.CIR.0000133317.49796.0E
  5. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American diabetes association and the American college of cardiology foundation. Diabetes Care 2008;31:811-822. https://doi.org/10.2337/dc08-9018
  6. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010- 2012 Committees. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Eur Heart J 2011;32:1769-1818. https://doi.org/10.1093/eurheartj/ehr158
  7. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/ AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889-2934. https://doi.org/10.1016/j.jacc.2013.11.002
  8. American Association of Clinical Endocrinologists. Press statement [Internet]. Jacksonville (FL): American Association of Clinical Endocrinologists, c2013 [cited 2013 Dec 23]. Available from: http://media.aace.com/press-release/press-statement.